In an interview to CNBC-TV18, Bhaskar Narayana, chief financial officer of Natco Pharma says, FY13 should see atleast one abbreviated new drug application (ANDA) coming through. FY13 would be a very exciting year for the company because it should result in good boost to the revenues, he adds.
Tags : #Natco Pharma